KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Non-Current Debt (2021 - 2025)

Fulgent Genetics' Non-Current Debt history spans 3 years, with the latest figure at $2.5 million for Q4 2024.

  • For Q4 2024, Non-Current Debt fell 15.89% year-over-year to $2.5 million; the TTM value through Dec 2024 reached $2.5 million, down 15.89%, while the annual FY2024 figure was $2.5 million, 15.89% down from the prior year.
  • Non-Current Debt for Q4 2024 was $2.5 million at Fulgent Genetics, roughly flat from $2.5 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $5.9 million in Q3 2021 and bottomed at $2.5 million in Q2 2024.
  • The 3-year median for Non-Current Debt is $2.7 million (2023), against an average of $3.7 million.
  • The largest YoY upside for Non-Current Debt was 15.89% in 2024 against a maximum downside of 15.89% in 2024.
  • A 3-year view of Non-Current Debt shows it stood at $5.9 million in 2021, then crashed by 50.16% to $3.0 million in 2023, then fell by 15.89% to $2.5 million in 2024.
  • Per Business Quant, the three most recent readings for FLGT's Non-Current Debt are $2.5 million (Q4 2024), $2.5 million (Q3 2024), and $2.5 million (Q2 2024).